Jena / Frickenhausen, January 20th, 2016 – With the start of 2016 the distribution of the cervical cancer triage test GynTect® by Greiner Bio-One has started. For this purpose the internationally active company had closed a marketing and distribution partnership with oncgnostics GmbH, who has developed and produces the GynTect® test, prior to Medica 2015. The CE IVD mark which GynTect® received in October 2015 allows the utilization of the test in laboratories in whole Europe.

Read more

Jena (Germany), September 18th, 2015 – A new test for use in cervical cancer screening is CE-IVD marked in whole Europe with immediate effect. It may quickly yield reliable test results, which will allow to identify more cancer cases early and thus to yield better therapy outcome. Developed by the biotech startup oncgnostics (www.oncgnostics.com) GynTect detects changes in cells of the cervix uteri that may be indicative for the development or presence of cancer. In contrast to other methods available in cervical cancer screening GynTect will have the potential to decrease the high number of unnecessary cervical biopsies and surgeries.

Read more